INS1033 / Insmed - LARVOL DELTA

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants (clinicaltrials.gov) - P1 | N=116 | Not yet recruiting | Sponsor: Insmed Incorporated

New P1 trial

In July 2026, the Investigational New Drug (IND) filing for INS1033, Insmed's second dipeptidyl peptidase 1 (DPP1) inhibitor, was cleared by the FDA for patients with rheumatoid arthritis (RA). Insmed plans to initiate a Phase 1 trial in healthy volunteers in the third quarter of 2026. (PRNewswire)

IND • New P1 trial • Immunology • Rheumatoid Arthritis

Progress and Anticipated Milestones:…INS1033 (PRNewswire) - "Insmed's second dipeptidyl peptidase 1 (DPP1) inhibitor, INS1033, is currently advancing toward the clinic in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), with an initial IND filing expected in 2026."

IND • Inflammatory Bowel Disease • Rheumatoid Arthritis